The global oncolytic virus cancer therapy market is poised for exceptional growth, expanding from an estimated USD 36.87 million in 2025 to an impressive USD 386.89 million by 2035, marking a Compound ...

As per Vantage Market Research, the Global Oncolytic Virus Immunotherapy Market has been significantly growing over the years due to the increasing prevalence of cancer and the adoption of advanced ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...

Biotech company PsiVac is developing Ixovex-1, the first patented virus with a single base pair mutation able to replicate rapidly, opening potential new treatment options for solid tumors and beyond.

Intravenous; NDV: Newcastle disease virus; OS: Overall survival ... Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems.

Cold Genesys is a clinical-stage company developing an oncolytic virus (CG0070) for multiple tumor types as a single agent and in combination with immune system checkpoint inhibitors. Already with ...